Organization
Massachusetts General Hospital, Harvard Medical School, Boston, MA
2 abstracts
Abstract
NRG-GU012: Randomized phase II stereotactic ablative radiation therapy (SABR) for metastatic unresected renal cell carcinoma (RCC) receiving immunotherapy (SAMURAI).Org: NRG Oncology Statistics and Data Management Center, Philadelphia, PA, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, University Hospitals Seidman Cancer Center, Cleveland, OH, Massachusetts General Hospital, Harvard Medical School, Boston, MA, Radiology School of Medicine, University of California, San Francisco, San Francisco, CA,
Abstract
lidERA Breast Cancer (BC): Phase III adjuvant study of giredestrant vs. physician’s choice of endocrine therapy (PCET) in patients (pts) with estrogen receptor-positive, HER2-negative early BC (ER+, HER2– eBC).Org: NSABP Foundation and UPMC Hillman Cancer Center, Pittsburgh, PA, Massachusetts General Hospital, Harvard Medical School, Boston, MA, Breast Center, Department of Obstetrics and Gynecology and CCC Munich, LMU University Hospital, Munich, Germany, Dan L. Duncan Comprehensive Cancer Center at Baylor College of Medicine, Houston, TX, University of California Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA,